“Increasing Demand for Precision Medicine to Boost the Global Flow Cytometry in Oncology Market During 2021-26

According to MarkNtel Advisors, the Global Flow Cytometry in Oncology Market is expected to grow at a CAGR of around 11.2% during 2021-26. The snowballing demand for tailored therapy & precision medicine is the prime factor driving the global flow cytometry in oncology market.
Flow cytometry is extremely sensitive and can detect Minimal Residual Disease (MRD). The technology has rapidly expanded from basic research to clinical laboratories, mainly due to its underlying clinical utilities, especially in hematological malignancies. Hence, when only a small number of cancer cells are left, despite zero evidence of disease, flow cytometers assist in predicting recurrence, monitoring remission, and treatment planning.

Get a sample copy: https://www.marknteladvisors.com/query/request-sample/flow-cytometry-in-oncology-market.html

Key Questions Answered in the Study
1. What are the current & future trends in the Global Flow Cytometry in Oncology Market?
2. How has the industry been evolving in terms of geography & service adoption?
3. How has the competition been shaping across the globe, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Flow Cytometry in Oncology Market?
5. What are the customer orientation, purchase behavior, and expectations from the flow cytometry in oncology providers across the globe?

Diagnostic Laboratories Captures the Largest Share of the Global Flow Cytometry in Oncology Market
Diagnostic Laboratories are at the epicenter of end-users in the Global Flow Cytometry in Oncology Market and acquired around 35% of the market share. They offer a wide range of expertise in pathology & advanced cancer diagnostics based on flow cytometry technology. These labs are highly beneficial in conducting MRD detection in patients suffering from hematological malignancies.
Additionally, diagnostic laboratories often collaborate with physicians to form “physician-laboratory partnerships” that are rapidly growing due to the importance of flow cytometry-based cancer analysis in the field of hematological malignancy testing.

For detailed analysis: https://www.marknteladvisors.com/query/request-sample/flow-cytometry-in-oncology-market.html

“Global Flow Cytometry in Oncology Market Analysis, 2021” highlights insights on the market potential & opportunities, along with business strategies to enhance the overall market growth. The report offers an overview of leading market players and their recent developments. Moreover, the report provides incredible market opportunities & emerging trends to help stakeholders make appropriate decisions before investing.

Hematological Malignancies Acquired more than 80% Share of the Global Flow Cytometry in Oncology Market

Hematological Malignancies primarily include Lymphoma, Leukemia, Myeloma, etc. The use of flow cytometry has been an established base for diagnosing hematologic neoplasms, primarily for the identification of malignant cell types.

The surging demand for flow cytometry for patients with Hematological malignancies is mainly due to the increasing clinical burden associated with lymphoma, rising adoption of flow cytometry technology in the clinical setting, massively growing prominence for MRD assessment, and rapidly increasing utilization of novel therapeutics. However, the demand for flow cytometry for patients with Leukemia is expected to witness the fastest growth rate during 2021-26.

Share your requirements: https://www.marknteladvisors.com/query/request-sample/flow-cytometry-in-oncology-market.html

According to MarkNtel Advisors, the leading industry players in the Global Flow Cytometry in Oncology Market are Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Luminex Corporation, Sony Corporation, and Cytek Biosciences.

Market Segmentation:
1. By Type (Assay & Kits, Instruments, Reagents & Consumables, Software)
2. By Technology (Cell Based, Bead Based)
3. By Type of Cancer (Hematological Malignancies {Lymphoma, Leukemia, Myeloma}, Solid Tumors {Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer})
4. By Application (Translational Research, Clinical Applications {Screening & Diagnostics, Treatment Monitoring})
5. By End User (Diagnostic Laboratories, Hospitals and Healthcare Centers, Academic & Research Institutes)
6. By Region (North America, South America, Europe, Middle East & Africa, Asia Pacific)
7. By Country (US, Canada, Mexico, The UK, Germany, France, Italy, Spain, UAE, Saudi Arabia, South Africa, India, China, Japan, South Korea)
8. By Company (Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytognos, S.L., Danaher Corporation, Luminex Corporation, Sony Corporation, Cytek Biosciences)

MarkNtel Advisors
1147 88AVE, Delta, British Columbia, BC,V4C,3B8, CANADA
Email: sales@marknteladvisors.com
Tel: +1 604 800 2671
Website: https://www.marknteladvisors.com

About us:
MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.